IntrinsicIntrinsic
← All summaries

Cingulate Inc.

CING
Financials & Chart →

Business Summary

Cingulate Inc. is a biopharmaceutical company focused on developing next-generation pharmaceutical products using its proprietary Precision Timed Release (PTR) drug delivery platform technology . The company's core business model revolves around developing once-daily, multi-dose tablets designed to improve patient lives by addressing burdensome daily dosing regimens and suboptimal treatment outcomes for frequently diagnosed conditions . The PTR platform incorporates a proprietary Erosion Barrier Layer (EBL) to enable drug substance release at specific, pre-defined time intervals . The primary customer segments targeted are patients suffering from Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety . The company generates revenue through product sales if regulatory approval is achieved, or through payments from collaboration or license agreements . As of December 31, 2025, Cingulate has not generated any revenue from product sales .

Cingulate is targeting the ADHD treatment market, which had an estimated U.S. market size of approximately 100 million annual prescriptions of stimulants as of September 2025 . The average branded long-acting stimulant wholesale acquisition cost (WAC) is $495 per prescription . The company estimates that a 1% market share capture in this market would represent approximately $250 million to $300 million in annual revenue, less rebates and discounts . Stimulants are the most commonly prescribed class of medications for ADHD, accounting for approximately 90% of all ADHD medication prescriptions in the U.S. during the year ended September 30, 2025 . The company also targets the anxiety treatment market, where U.S. sales of buspirone accounted for over $1 billion in 2025 within the $15.2 billion anxiety and depression market .

The company's product pipeline includes two first-line stimulant medications for ADHD: CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) . Both are designed to provide immediate onset of action (within 30 minutes), entire 'active-day' duration, eliminate the need for 'booster/recovery' doses, minimize rebound/crash symptoms, and offer favorable tolerability . CTx-1301 is a trimodal extended-release tablet providing three distinct releases of dexmethylphenidate hydrochloride: an initial immediate-release dose (35% of total daily dose) within five to six minutes, a first delayed, sustained release (45% of total daily dose) three hours after administration, and a second delayed, immediate release (20% of total daily dose) seven hours after administration . CTx-1302 has a similar trimodal release profile with 45% immediate release, 35% first delayed sustained release, and 20% second delayed immediate release . The company also has CTx-2103 (buspirone) in development for anxiety, designed as a once-daily administration using the PTR platform .

For the year ended December 31, 2025, Cingulate reported a net loss of $22.4 million , compared to a net loss of $16.6 million for the year ended December 31, 2024 . The accumulated deficit as of December 31, 2025, was $132.4 million . Research and development expenses were $14.7 million in 2025 and $11.0 million in 2024 . General and administrative expenses were $7.7 million in 2025 and $5.6 million in 2024 . The company has not generated any revenue since its inception .

Year-over-year, the net loss increased from $16.6 million in 2024 to $22.4 million in 2025 [13, 14]. Research and development expenses increased by $3.7 million from $11.0 million in 2024 to $14.7 million in 2025 [16, 17]. General and administrative expenses increased by $2.1 million from $5.6 million in 2024 to $7.7 million in 2025 [18, 19].

During the reported period, Cingulate submitted a New Drug Application (NDA) for CTx-1301 to the FDA on July 31, 2025 , which was accepted for review on September 29, 2025 . The FDA assigned a PDUFA target action date of May 31, 2026 . The company received a first European patent for CTx-1301 on August 14, 2024, and a second on December 17, 2025, providing protection until 2042 . A Notice of Allowance for a U.S. patent application covering CTx-1301 was issued on March 17, 2026 . Cingulate entered into a commercial supply agreement with CoreRx, Inc. (dba Bend Bioscience) on August 27, 2025, for the manufacture of CTx-1301 . In May 2025, a joint commercialization agreement with Indegene, Inc. was replaced with a master services agreement for commercialization services for CTx-1301 . In November 2025, a licensing and services master agreement was entered into with IQVIA Inc. for commercialization services, including field sales and national account management, for CTx-1301 . The company completed a one-for-twelve reverse stock split on August 9, 2024 .

Business Outlook

Cingulate anticipates continued significant expenses and operating losses in the near term as it seeks regulatory approval for CTx-1301, continues research and development activities for existing and new product candidates, primarily CTx-1301, continues manufacturing activities for CTx-1301, advances commercialization efforts for CTx-1301, and operates as a public company . The company believes its cash on hand will satisfy capital needs late into the fourth quarter of 2026 under its current business plan, which primarily includes activities related to seeking regulatory approval and pre-commercialization efforts for CTx-1301 . Additional capital will be required to advance other programs .

A major growth area for Cingulate is the potential commercialization of CTx-1301 for ADHD. The NDA for CTx-1301 was submitted to the FDA on July 31, 2025, and accepted for review on September 29, 2025, with a PDUFA target action date of May 31, 2026 [20, 21, 22]. If approved, Cingulate plans to partner with Indegene, Inc. for commercialization services in the United States, including marketing, market access and pricing, commercial operations, and an omnichannel platform, on a fee-for-service basis . Additionally, Cingulate intends to partner with IQVIA Inc. for field sales and national account management services for CTx-1301 . The company aims to provide CTx-1301 in eight dosage strengths, ranging from 6.25mg to 50mg of dexmethylphenidate, to allow for proper titration and optimization of patient dosing .

Another growth area is the development of CTx-2103 for anxiety. The company received FDA feedback on the regulatory pathway for CTx-2103, suggesting it may be approved under the 505(b)(2) pathway, which typically requires less time and resources than a full NDA pathway . CTx-2103 is designed as a once-daily, modified-release tablet of buspirone, aiming to differentiate itself from standard multi-dose treatments . Additional capital resources will be required to continue the development of CTx-2103 .

Cingulate also plans to advance the development of CTx-1302 for ADHD, pending additional capital resources . The proposed clinical program for CTx-1302 includes Phase 1/2 clinical pharmacology studies and Phase 3 clinical efficacy and safety trials, with Phase 1/2 trials expected to enroll approximately 100 patients and Phase 3 trials approximately 500 patients . The company expects to file a 505(b)(2) NDA for CTx-1302, referencing Dexedrine Spansule .

Operationally, Cingulate expects its general and administrative expenses to increase as it expands headcount to support growing operations, including potential commercialization of CTx-1301, and incurs costs related to pre-commercialization activities and operating as a public company . The company also anticipates increased research and development expenses as it continues clinical development for its product candidates and adds new PTR product candidates to its pipeline, noting that later-stage clinical development generally has higher costs due to increased size and duration of trials . Manufacturing of CTx-1301 will occur at a dedicated suite within Bend Bioscience's Gainesville, GA facility, outfitted with Cingulate's equipment . The FDA conducted a pre-approval inspection of this facility in February 2026, issuing a Form 483 with three observations, two related to the facility and one specific to CTx-1301, which the CDMO is addressing .

For capital allocation, Cingulate expects to fund research and development expenses from current cash and cash equivalents and any future equity or debt financings, or other capital sources . The company does not anticipate paying any cash dividends on its common stock in the foreseeable future, intending to retain future earnings to finance business operations and expansion .

Management has explicitly flagged several structural headwinds and execution risks. The company is dependent primarily on the successful development and commercialization of CTx-1301, CTx-1302, and CTx-2103, none of which are yet approved . There is no guarantee of regulatory approval for these candidates . The commercial success of approved product candidates depends on market acceptance by physicians, patients, and third-party payors . Social issues surrounding the abuse of opioids and stimulants, including law enforcement concerns over diversion and regulatory efforts, could decrease the potential market for the company's product candidates . The company relies on limited, single sources of supply for CTx-1301 and CTx-1302, which are scheduled products, and any disruption could impact production and sales . Cingulate also relies on third parties for manufacturing, clinical trials, regulatory submissions, and commercialization services, and their unsatisfactory performance or non-compliance could significantly impact the business .

Geographic, regulatory, and macro factors identified as constraints include the potential for changes in FDA policies or additional government regulations that could prevent, limit, or delay marketing approval of product candidates . Government initiatives, such as the "Make America Healthy Again Commission," could reevaluate the regulatory landscape for ADHD and anxiety treatments, potentially leading to stricter clinical trial requirements, extended approval timelines, or reduced market access . Unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives could harm the business by increasing cost containment pressures and challenging prices . Foreign market penetration is subject to additional regulatory burdens and risks, including compliance with foreign regulatory, tax, accounting, and legal requirements, and reduced intellectual property protection in some countries .

Risk Factors

Cingulate faces material risks including its limited operating history and the need for significant additional capital to continue operations, with an accumulated deficit of $132.4 million as of December 31, 2025 . The company's ability to continue as a going concern is in substantial doubt without further funding . Dependence on the successful development and commercialization of CTx-1301 is high, and failure to secure FDA approval by the PDUFA target action date of May 31, 2026, or at all, would severely limit revenue generation [22, 42]. The recent FDA pre-approval inspection of the CDMO's facility for CTx-1301 resulted in a Form 483 with three observations, posing a risk of further delays or denial of approval . The company relies on single-source third-party manufacturers and suppliers for controlled substances, and any disruption or non-compliance with cGMP or DEA regulations could interrupt supply and delay development or commercialization . The 2025 Note Purchase Agreement with Avondale Capital, LLC for $6,570,000 contains restrictive covenants and default provisions, including a potential 15% increase in outstanding balance for a "Major Trigger Event" and 5% for a "Minor Trigger Event," and the right for the lender to redeem up to $660,000 per month starting May 7, 2026 . Failure to comply with these terms or make redemptions could result in significant detrimental effects . The commercial success of product candidates, if approved, depends on market acceptance by physicians, patients, and third-party payors, which may be hindered by cost containment measures, unfavorable pricing regulations, or competition from generic products [43, 49]. Social issues and regulatory efforts to combat stimulant abuse could decrease the market for CTx-1301 and CTx-1302 . The evolving regulatory framework for AI technologies may also impose additional costs and liabilities .

Management Priorities

Management emphasizes its focus on leveraging the proprietary Precision Timed Release (PTR) drug delivery platform to develop next-generation pharmaceutical products, initially targeting ADHD and anxiety, to improve patient lives by addressing burdensome daily dosing and suboptimal treatment outcomes . A key strategic priority is obtaining regulatory approval for CTx-1301 for ADHD, with an NDA submitted to the FDA on July 31, 2025, and a PDUFA target action date of May 31, 2026 [20, 22]. Following potential approval, successfully commercializing CTx-1301 through partnerships with Indegene and IQVIA for marketing, sales, and market access is another core objective [26, 27]. The company also highlights advancing clinical trials for CTx-2103 for anxiety and CTx-1302 for ADHD, both of which require additional capital resources [34, 35]. Management's overall tone indicates a commitment to expanding the pipeline by identifying additional therapeutic areas with significant unmet medical needs and billion-dollar revenue potential, leveraging the 505(b)(2) development pathway, and continuously strengthening its intellectual property portfolio . The company acknowledges the need for significant additional capital to support planned development and commercialization activities, estimating current cash will satisfy capital needs late into the fourth quarter of 2026 under the current business plan .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 7, MD&A — Components of Operating Results — Revenue
  3. [3] Item 1, Business — Overview
  4. [4] Item 1, Business — Overview
  5. [5] Item 1, Business — Overview
  6. [6] Item 1, Business — ADHD Overview and Drawbacks of Current Therapies
  7. [7] Item 1, Business — Overview
  8. [8] Item 1, Business — Overview
  9. [9] Item 1, Business — Overview
  10. [10] Item 1, Business — Our Lead Candidate CTx-1301: Dexmethylphenidate for the Treatment of ADHD in 6 Years and Older
  11. [11] Item 1, Business — CTx-1302: Dextroamphetamine for the treatment of ADHD in 6 years and older
  12. [12] Item 1, Business — Overview
  13. [13] Item 7, MD&A — Results of Operations — Comparison of the years ended December 31, 2025 and December 31, 2024
  14. [14] Item 7, MD&A — Results of Operations — Comparison of the years ended December 31, 2025 and December 31, 2024
  15. [15] Item 7, MD&A — Overview
  16. [16] Item 7, MD&A — Results of Operations — Comparison of the years ended December 31, 2025 and December 31, 2024
  17. [17] Item 7, MD&A — Results of Operations — Comparison of the years ended December 31, 2025 and December 31, 2024
  18. [18] Item 7, MD&A — Results of Operations — Comparison of the years ended December 31, 2025 and December 31, 2024
  19. [19] Item 7, MD&A — Results of Operations — Comparison of the years ended December 31, 2025 and December 31, 2024
  20. [20] Item 1, Business — CTx-1301
  21. [21] Item 1, Business — CTx-1301
  22. [22] Item 1, Business — CTx-1301
  23. [23] Item 1, Business — CTx-1301
  24. [24] Item 1, Business — CTx-1301
  25. [25] Item 1, Business — Manufacturing — Overview
  26. [26] Item 1, Business — Commercialization
  27. [27] Item 1, Business — Commercialization
  28. [28] Item 7, MD&A — 2024 Reverse Stock Split
  29. [29] Item 7, MD&A — Overview
  30. [30] Item 7, MD&A — Overview
  31. [31] Item 1, Business — Availability in Eight Dosage Strengths at Launch and Single-Enantiomer API Selection
  32. [32] Item 1, Business — CTx-2103
  33. [33] Item 1, Business — CTx-2103: Buspirone product candidate for the treatment of anxiety related disorders
  34. [34] Item 1, Business — Our Strategy
  35. [35] Item 1, Business — Our Strategy
  36. [36] Item 1, Business — Our CTx-1302 Clinical Development Program
  37. [37] Item 1, Business — Our CTx-1302 Clinical Development Program
  38. [38] Item 7, MD&A — General and Administrative Expenses
  39. [39] Item 7, MD&A — Research and Development Expenses
  40. [40] Item 1, Business — Our Strategy
  41. [41] Item 5, Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities — Dividend Policy
  42. [42] Item 1A, Risk Factors — Summary of Risks
  43. [43] Item 1A, Risk Factors — Summary of Risks
  44. [44] Item 1A, Risk Factors — Summary of Risks
  45. [45] Item 1A, Risk Factors — Summary of Risks
  46. [46] Item 1A, Risk Factors — Summary of Risks
  47. [47] Item 1A, Risk Factors — Premarket review of our product candidates by the FDA or other regulatory authorities is a lengthy and uncertain process and approval may be delayed, limited or denied, any of which would adversely affect our ability to generate operating revenues.
  48. [48] Item 1A, Risk Factors — Government initiatives such as the Make America Healthy Again Commission could affect the development and approval of our product candidates
  49. [49] Item 1A, Risk Factors — Unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives could harm our business in the future.
  50. [50] Item 1A, Risk Factors — Our future growth depends, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.
  51. [51] Item 1A, Risk Factors — The report of our independent registered public accounting firm for the fiscal years ended December 31, 2025 and 2024 contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern.
  52. [52] Item 7, MD&A — Debt Issuance
  53. [53] Item 1A, Risk Factors — The note purchase agreement and note issued by us in November 2025 contain restrictive covenants and adjustments in the event we default on the Note that may limit our operating flexibility and impact our operations.
  54. [54] Item 1A, Risk Factors — The note purchase agreement and note issued by us in November 2025 contain restrictive covenants and adjustments in the event we default on the Note that may limit our operating flexibility and impact our operations.
  55. [55] Item 1A, Risk Factors — The regulatory framework for use of AI technologies in our business is rapidly evolving and any failure or perceived failure by us or our employees, representatives, contractors, consultants, CDMO, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business and results of operations.
  56. [56] Item 1, Business — Our Strategy

Analysis on 5/20/2026